Core Viewpoint - Fosen Pharmaceutical's subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration of China for the listing application of Enzalutamide soft capsules, indicating a significant advancement in the treatment options for specific prostate cancer patients [1] Group 1: Product Approval - The approved indication for Enzalutamide includes treatment for high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC) in adult patients [1] - It is also approved for asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (CRPC) in adult patients who have failed androgen deprivation therapy (ADT) and have not received chemotherapy [1] Group 2: Mechanism of Action - Enzalutamide acts as an androgen receptor inhibitor, targeting the androgen receptor signaling pathway by competitively inhibiting the binding of androgens to the androgen receptor [1] - The drug suppresses androgen receptor nuclear translocation and the interaction between the androgen receptor and DNA [1] - The primary metabolite, N-desmethyl-Enzalutamide, exhibits similar in vitro activity to Enzalutamide [1] Group 3: Efficacy - In vitro studies show that Enzalutamide can inhibit the proliferation of prostate cancer cells and induce apoptosis in these cells [1] - In mouse models of prostate cancer xenografts, Enzalutamide has been shown to reduce tumor volume [1]

Core Viewpoint - Fosen Pharmaceutical's subsidiary has received approval from the National Medical Products Administration of China for the marketing application of Enzalutamide soft capsules, targeting specific types of prostate cancer [1] Company Summary - Fosen Pharmaceutical's subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., has developed Enzalutamide soft capsules [1] - The approved indications include treatment for high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC) in adult patients and asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (CRPC) in adults who have not received chemotherapy after androgen deprivation therapy (ADT) failure [1] Industry Summary - Prostate cancer is the second most common malignancy among men globally and the fifth leading cause of cancer-related deaths [1] - The incidence of prostate cancer in China is lower than in Western countries but has been increasing in recent years [1] - Enzalutamide is an androgen receptor inhibitor that competes with androgens for binding to androgen receptors, inhibiting their nuclear translocation and interaction with DNA [1] - Enzalutamide has shown efficacy in inhibiting prostate cancer cell proliferation and inducing cell death in vitro, and it has reduced tumor volume in mouse models of prostate cancer [1] - Enzalutamide was first launched in the United States in 2012, followed by the European Union in 2013, and was approved for use in China in 2019 [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Fusen Pharmaceutical Company Limited 福 森 藥 業 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1652） 自願公告 「恩扎盧胺軟膠囊」獲批上市 福森藥業有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」） 欣然宣佈，本集團之全資附屬公司嘉亨（ 珠海橫琴 ）醫藥科技有限公司研發的「恩 扎 盧 胺 軟 膠 囊」， 上 市 申 請 已 獲 得 中 華 人 民 共 和 國 國 家 藥 品 監 督 管 理 局 批 准 ， 批 准 用 於 以 下 疾 病 的 治 療 ： 有 高 危 轉 移 風 險 的 非 轉 移 性 去 勢 抵 抗 性 前 列 腺 癌 (NM - CRPC)成年患者；雄激素剝奪治療(ADT)失敗後無症狀或有輕微症狀且未接受化療 的轉移性去勢抵抗性前列腺癌( ...

Group 1 - The core point of the article is that Fosen Pharmaceutical (01652) announced that one of its products, Metformin and Empagliflozin Tablets (containing 500mg Metformin Hydrochloride and 5mg Empagliflozin), is expected to win a bid in China's 11th national centralized drug procurement tender scheduled for October 27, 2025 [1] Group 2 - The product involved in the tender is a combination of Metformin and Empagliflozin, which are commonly used in the treatment of type 2 diabetes [1] - Winning the bid could enhance the company's market presence and sales potential in the competitive pharmaceutical landscape in China [1] - The announcement reflects the company's ongoing efforts to expand its product portfolio and participate in national procurement initiatives [1]

Core Viewpoint - Fosen Pharmaceutical (01652.HK) announced that one of its products, Metformin and Ertugliflozin Tablets (containing 500mg Metformin Hydrochloride and 5mg Ertugliflozin), is expected to win a bid in China's 11th national centralized drug procurement on October 27, 2025 [1] Group 1 - Fosen Pharmaceutical is participating in the 11th round of national drug procurement in China [1] - The product involved in the bidding is a combination of Metformin and Ertugliflozin [1] - The specific formulation includes 500mg of Metformin Hydrochloride and 5mg of Ertugliflozin [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Fusen Pharmaceutical Company Limited 福 森 藥 業 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1652） 自願公告 全國藥品集中採購擬中選結果 福森藥業有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」） 欣然宣布，於二零二五年十月二十七日的中國第十一批全國藥品集中採購招標結 果中，本集團其中一個產品擬中標：二甲雙胍恩格列淨片(I)（ 鹽酸二甲雙胍500mg 和恩格列淨5 mg ）。 承董事會命 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展 情況。 福森藥業有限公司 主席兼執行董事 曹智銘先生 香港，2025年10月30日 於 本 公 告 日 期 ， 本 公 司 董 事 會 包 括 執 行 董 事 曹 智 銘 先 生（ 主 席 ）、 侯 ...

（於開曼群島註冊成立的有限公司） 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Fusen Pharmaceutical Company Limited 福 森 藥 業 有 限 公 司 （股份代號：1652） 補充公告 有關出售 河南福森智慧節能科技有限公司全部股權之 須予披露交易 茲 提 述本 公 司 所刊 發 日 期 為2025 年 9 月 19 日 有關 出 售 事項 之 公 告（「該 公 告」）。 除 另有註明外，本公告所用詞彙與該公告所界定者具有相同涵義。 本公司謹此向股東及本公司潛在投資者提供有關出售事項之額外資料。 釐定代價之基準 誠如該公告所披露，代價乃賣方與買方按一般商業條款公平磋商後釐定，並已考 慮（ 其 中 包 括 ）估 值 報 告（「估 值 報 告」）所 載 目 標 公 司 於 參 考 日 期（ 即 2025 年 3 月 31 日 ）之評估資產淨值約人民幣73 ...

Economic Performance and Comparison - In August 2025, major economic indicators in China showed signs of slowing down, with industrial production and investment facing pressures due to external tariff policies and internal "anti-involution" governance [11][14] - The industrial added value in Henan province grew by 8.2% year-on-year in August, outperforming the national average by 3.0 percentage points, with strong performance in upstream mining and processing industries [21][24] - Social retail sales in Henan reached 2264.55 billion yuan in August, with a year-on-year growth of 3.7%, slightly above the national average [22][24] Investment Trends - From January to August 2025, fixed asset investment in Henan increased by 4.7%, surpassing the national growth rate of 4.2%, with industrial investment showing a robust growth of 20.5% [23][28] - The real estate market in Henan continued to show weakness, with real estate development investment declining by 8.1% year-on-year [23][24] Policy Tracking - In September 2025, the financial regulatory authorities introduced a series of policies aimed at releasing consumption potential, optimizing resource allocation, and promoting digital transformation in industries [29][30] - The Henan provincial government launched several initiatives to support technological innovation and stabilize the real estate market, including a plan to enhance financial services for high-tech and green enterprises [36][38] Securities Market Performance - In September 2025, the Henan Index rose by 3.36%, outperforming both the Shanghai Composite Index and the CSI 300 Index, with a cumulative increase of 32.92% in the first nine months of the year [59][61] - The bond financing scale in Henan reached 370.72 billion yuan in September, marking an 8.18% increase from the previous month [42][47]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 福森藥業有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01652 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 739,301,000 | | 0 | | 739,301,000 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 739,301,000 | | 0 | | 739,301,000 | 第 2 頁 共 10 頁 v 1.1.1 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | ...

Group 1 - The company announced that Mr. Shi Yongjin will resign as an independent non-executive director effective September 30, 2025, and will no longer serve as the chairman of the audit committee [1] - Mr. Yu Haoming has been appointed as an independent non-executive director and a member of the audit committee [1] - Mr. Li Guodong has been appointed as the chairman of the audit committee [1]